**Fazirsiran Study for Liver Disease:** This research checks if fazirsiran, a new drug, can help people with liver damage caused by a faulty protein called Alpha-1 Antitrypsin. The trial compares fazirsiran to a placebo (a fake treatment) to see if it reduces liver scarring and other liver damage.

**Participation Details:**

• Participants will receive either fazirsiran or a placebo.
• Liver biopsies, a small piece of liver tissue, will be collected twice.
• Participants must be between 18-75 years and meet specific health criteria.

**Consider Before Joining:**

• **Treatment:** You might receive the actual drug or a placebo.
• **Visits:** You will need to undergo liver biopsies and other tests.
• **Risks:** Side effects may occur, and not everyone can join.

Eligibility requires a specific gene type and liver condition. You cannot join if you have other liver diseases or recent drug abuse. This study aims to find out if fazirsiran can safely help reduce liver damage and scarring. If you’re interested, ensuring you meet the health requirements is important.